



OFFICE OF THE DIRECTOR

Kate Brown, Governor



500 Summer St NE E20
Salem, OR 97301
Voice: 503-947-2340
Fax: 503-947-2341
www.Oregon.Gov/OHA
www.health.oregon.gov

OFFICIAL WEBSITE NOTICE
Posting Date: February 10, 2021

RECOMMENDATIONS OF DRUG USE REVIEW / PHARMACY AND THERAPEUTICS COMMITTEE

The Oregon Drug Use Review / Pharmacy and Therapeutics Committee met virtually on Thursday, February 4, 2021. The Committee considered in order of priority: the safety and efficacy of the drugs being considered; the ability of Oregonians to access effective prescription drugs that are appropriate for their clinical conditions; and substantial differences in costs of drugs within the same therapeutic class. Based upon the clinical information presented by staffⁱ and all public comment offered,ⁱⁱ while considering the impact on special populations, the Committee makes the following recommendations for Drug Use Review, the Oregon Practitioner-Managed Prescription Drug Plan (PMPDP), or for any other preferred drug list established by the Oregon Health Authority:

Drug Use Review (DUR) Recommendations:

Orphan Drug Policy Updates

The Committee recommended updating Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of ZokinvyTM (lonafarnib) and OxlumioTM (lumasiran) based on FDA-approved labeling.

Oncology Policy Updates

The Committee recommended adding the following new FDA-approved antineoplastic agents to Table 1 in the Oncology Agents PA criteria: MargenzaTM (margetuximab-cmkb); Danyelza[®] (naxitamab-gqgk); and OrgovyzTM (relugolix).

Practitioner-Managed Prescription Drug Plan (PMPDP) Recommendations:

Anticoagulant Literature Scan

The Committee recommended making no changes to the PMPDP based on clinical evidence. After comparative cost consideration in executive session, the Committee recommended making Fragmin® (dalteparin syringes) non-preferred on the PMPDP.

DRUG	CHANGE
Fragmin® (dalteparin syringes)	Make non-preferred on the PMPDP

Duchenne Muscular Dystrophy (DMD) Class Update and Drug Effectiveness Review Project (DERP) Summary Report with New Drug Evaluation (NDE)

The Committee recommended updating the prior authorization (PA) criteria for DMD to include Viltepto® (viltolarsen) to ensure medically appropriate use. After comparative cost consideration in executive session, the Committee recommended making no changes to the PMPDP.

Acne Class Update with NDE

The Committee recommended designating Winlevi® (clascoterone) non-preferred on the PMPDP based on clinical evidence. After comparative cost consideration in executive session, the Committee recommended making benzoyl peroxide (BPO) lotion and erythromycin/BPO gel (Benzamycin® & generic) preferred; and BPO towelette non-preferred on the PMPDP.

DRUG	CHANGE
Winlevi® (clascoterone)	Make non-preferred on the PMPDP
benzoyl peroxide (BPO) lotion	Make preferred on the PMPDP
erythromycin/BPO gel	Make preferred on the PMPDP
BPO towelette	Make non-preferred on the PMPDP

Treatments for Peanut Allergy DERP Summary Report

The Committee recommended creating a Peanut Desensitization PMPDP class and to designate Palforzia® [peanut (arachis hypogaea) allergen powder-dnf] as non-preferred on the PMPDP based on clinical evidence.

DRUG	CHANGE
Palforzia® (peanut allergen powder-dnf)	Make non-preferred on the PMPDP

Tobacco Smoking Cessation Literature Scan

The Committee recommended making no changes to the PMPDP based on clinical evidence. The Committee recommended updating the Smoking Cessation PA criteria as proposed and to only apply it to non-preferred drugs. After comparative cost

consideration in executive session, the Committee recommended making no changes to the PMPDP.

Antidepressants Class Update

The Committee recommended making no changes to the PMPDP based on clinical evidence and to update the esketamine safety edit to accommodate the new indication. The Committee recommended amending the proposed renewal criteria as presented to include an assessment of adherence to oral antidepressant therapy. After comparative cost consideration in executive session, the Committee recommended making duloxetine DR capsules, bupropion HCL XL 24H tablets (Wellbutrin XL® & associated generics), and desvenlafaxine succinate ER 24H tablets preferred; and make amoxapine tablets voluntary non-preferred. The Committee also requested staff explore RetroDUR opportunities for dose consolidation with vortioxetine and change forms to switch utilization from desvenlafaxine 24H ER tabs to desvenlafaxine succinate 24H ER tabs.

DRUG	CHANGE
duloxetine DR capsules	Make preferred on the PMPDP
bupropion HCL XL 24H tablets	Make preferred on the PMPDP
desvenlafaxine succinate ER 24H tablets	Make preferred on the PMPDP
amoxapine tablets	Make non-preferred on the PMPDP

NSAID Class Update

The Committee recommended making no changes to the PMPDP based on clinical evidence. After comparative cost consideration in executive session, the Committee recommended making celecoxib (brand and generic) preferred; and make Qmiiz ODT™ (meloxicam), fluribiprofen and ketorolac non-preferred.

DRUG	CHANGE
celecoxib	Make preferred on the PMPDP
Qmiiz ODT™ (meloxicam)	Make non-preferred on the PMPDP
fluribiprofen	Make non-preferred on the PMPDP
ketorolac	Make non-preferred on the PMPDP

The Committee has made these recommendations to the Oregon Health Authority for approval by the Director of the Oregon Health Authority.

APPROVAL BY THE DIRECTOR OF THE OREGON HEALTH AUTHORITY

The recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee are approved. Recommendations with respect to the inclusion of a drug on the Practitioner-Managed Prescription Drug Plan will be put into place no earlier than 7 days from the date this notice is posted on the web site.



Patrick M. Allen
Director, Oregon Health Authority

2/10/2021

Approval date

A request for reconsideration of this decision to adopt the recommendations of the Drug Use Review / Pharmacy and Therapeutics Committee must be filed with and received by the Director no later than 7 calendar days from the date of this notice. ORS 414.361(6)(b).

ⁱ https://www.orpdl.org/durm/meetings/meetingdocs/2021_02_04/finals/2021_02_04_PnT_Complete.pdf

ⁱⁱ https://www.orpdl.org/durm/meetings/meetingdocs/2021_02_04/finals/2021_02_04_WrittenTestimony.pdf